Misuse of medicines in the European union: A systematic review of the literature

European Addiction Research

Volumn 18, Issue 5, 2012, Pages 228-245

  Casati, Alicia ^a   Sedefov, Roumen ^b   Pfeiffer Gerschel, Tim ^a,b  

^a IFT INSTITUT FÜR THERAPIEFORSCHUNG   (Germany)

^b German Focal Point   (Germany)

Author keywords

Abuse of prescription drugs; Analgesics opioids; Dependence on prescription drugs; European Union; Heroin maintenance treatment; Medicine misuse; Sedatives

Indexed keywords

ALCOHOL; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CARISOPRODOL; COCAINE; CODEINE; DIAMORPHINE; DIAZEPAM; ERGOT DERIVATIVE; FENTANYL; FENTANYL CITRATE; HYPNOTIC AGENT; IBUPROFEN; METHADONE; METHYLPHENIDATE; OPIATE; PARACETAMOL; PSEUDOEPHEDRINE; SEDATIVE AGENT; TETRAHYDROCANNABINOL; TRAMADOL; TRANQUILIZER; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ALCOHOLISM; ANXIETY DISORDER; ARTICLE; CANCER PAIN; CHRONIC PAIN; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG INDUCED HEADACHE; DRUG MISUSE; DRUG OVERDOSE; EUROPEAN UNION; FRANCE; GERMANY; HEALTH CARE POLICY; HEROIN DEPENDENCE; HIGH RISK POPULATION; HUMAN; INSOMNIA; IRELAND; ITALY; LOW BACK PAIN; MIGRAINE; OPIATE ADDICTION; PAIN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SLEEP DISORDER; SWEDEN; UNITED KINGDOM; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; EUROPEAN UNION; HUMANS; HYPNOTICS AND SEDATIVES; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG MISUSE; PRESCRIPTION DRUGS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84860877998     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000337028     Document Type: Article

References (81)

1. Report of the International Narcotics Control Board for 2006. International Narcotics Control Board. Geneva, United Nations, 2007
2. Hernandez SH, Nelson LS: Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 2010; 88: 307-317.
3. Glaeske G: Psychotrope und andere Arzneimittel mit Missbrauchs-und Abhängigkeitspotential (Psychotropic and other pharmaceuticals with abuse or dependence potential); in Deutsche Hauptstelle gegen die Suchtgefahren: Jahrbuch Sucht 2005. Geesthach, Neuland, 2005, pp 52-68.
4. Blanco C, Alderson D, Ogburn E, Grant BF, Nunes EV, Hatzenbuehler ML, Hasin DS: Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend 2007; 90: 252-260. (Pubitemid 47284719)
5. Kuehn BM: Prescription drug abuse rises globally. JAMA 2007; 297: 1306. (Pubitemid 46513252)
6. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A: The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med 2007; 8: 157-170.
7. Magrini N, Vaccheri A, Parma E, D'Alessandro R, Bottoni A, Occhionero M, Montanaro N: Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use (see comments). Eur J Clin Pharmacol 1996; 50: 19-25. (Pubitemid 26141503)
8. Zandstra SM, Furer JW, van de Lisdonk EH, van 't Hof M, Bor JHJ, van Weel C, Zitmann FG: Different study criteria affect the prevalence of benzodiazepine use. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 139-144. (Pubitemid 36097270)
9. Stillwell G, Fountain J: Benzodiazepine Use -A Report of a Survey of Benzodiazepine Consumption in the Member Countries of the Pompidou Group. Geneva, World Health Organization, 2002.
10. Barbui C, Gregis M, Zappa M: A cross-sectional audit of benzodiazepine use among general practice patients. Acta Psychiatr Scand 1998; 97: 153-156. (Pubitemid 28145462)
11. Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Bégaud B, Verdoux H, Moore N: Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004; 60: 523-529. (Pubitemid 39350165)
12. Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M: Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator. CNS Drugs 2010; 24: 611-620.
13. Lader M: Benzodiazepines revisited -will we ever learn? Addiction 2011; 106: 2086-2109.
14. Holzbach R: Benzodiazepine: longterm use and addiction (in German). Fortschr Neurol Psych 2012; 78: 425-431.
15. Heberlein A, Bleich S, Kornhuber J, Hillemacher T: Benzodiazepine dependence: causalities and treatment options. Fortschr Neurol Psych 2012; 77: 7-15.
16. Ashton H: The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18: 249-255. (Pubitemid 40586107)
17. Lalive AL, Rudolph U, Luescher C, Tan KR: Is there a way to curb benzodiazepine addiction? Swiss Med Wkly 2011; 141:w13277.
18. Siriwardena AN, Qureshi Z, Gibson S, Collier S, Latham M: GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics. Br J Gen Pract 2006; 56: 964-967. (Pubitemid 44941796)
19. Liebrenz M, Boesch L, Stohler R, Caflisch C: Agonist substitution -a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction 2010; 105: 1870-1874.
20. Kanayama G, Hudson JI, Pope HG: Illicit anabolic-androgenic steroid use. Horm Behav 2010; 58: 111-121.
21. Mattila VM, Rimpelä A, Jormanainen V, Sahi T, Pihlajamäki H: Anabolic-androgenic steroid use among young Finnish males. Scand J Med Sci Sports 2010; 20: 330-335.
22. Wanjek B, Rosendahl J, Strauss B, Gabriel HH: Doping, drugs and drug abuse among adolescents in the state of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med 2007; 28: 346-353. (Pubitemid 46640303)
23. Dodge T, Hoagland MF: The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend 2011; 114: 100-109.
24. Handelsman DJ: Androgen misuse and abuse. Best Pract Res Clin Endocrinol Metab 2011; 25: 377-389.
25. Palmié N, Condemine-Piron C, Peyrière H, Eiden C, Blayac J: Dependence on anabolic androgenic steroids in sport: a retrospective study of phone calls at 'ecoute dopage' hotline. Fundam Clin Pharmacol 2011; 25(s1):20.
26. Sjöqvist F, Garle M, Rane A: Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 2008; 371: 1872-1882. (Pubitemid 351734542)
27. Barrett SP, Meisner JR, Stewart SH: What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev 2008; 1: 255-262.
28. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, American Psychiatric Association, 2000.
29. Kufner H, Rosner S: Monitoring of the misuse of prescription drugs by clients of outpatient addiction treatment centres (PHARMON, formerly: Ebis-med) -Monitoring of medication misuse (in German). Gesundheitswesen 2008; 70: 305-314. (Pubitemid 352007172)
30. Gjerden P, Bramness JG, Slordal L: The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 2009; 67: 228-233.
31. Frauger E, Thirion X, Chanut C, Natali F, Debruyne D, Saillard C, Pradel V, Reggio P, Micallef J: Misuse of trihexyphenidyl (Artane Parkinane) : recent trends (in French). Therapie 2003; 58: 541-547. (Pubitemid 38327276)
32. Orriols L, Gaillard J, Lapeyre-Mestre M, Roussin A: Evaluation of abuse and dependence on drugs used for self-medication a pharmacoepidemiological pilot study based on community pharmacies in France. Drug Safety 2009; 32: 859-873.
33. MacFadyen L, Eadie D, McGowan T: Community pharmacists' experience of over-thecounter medicine misuse in Scotland. J R Soc Promot Health 2001; 121: 185-192. (Pubitemid 32952007)
34. Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K: Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011; 44: 60-66.
35. Frauger E, Pauly V, Pradel V, Reggio P, Coudert H, Thirion X, Micallef J: Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database main trends from 2005 to 2008. CNS Drugs 2011; 25: 415-424.
36. Porteous T, Bond C, Hannaford P, Sinclair H: How and why are non-prescription analgesics used in Scotland? Fam Pract 2005; 22: 78-85. (Pubitemid 40309609)
37. Fach M, Bischof G, Schmidt C, Rumpf HJ: Prevalence of dependence on prescription drugs and associated mental disorders in a representative sample of general hospital patients. Gen Hosp Psychiatry 2007; 29: 257-263. (Pubitemid 46678218)
38. Fredheim OMS, Skurtveit S, Moroz A, Breivik H, Borchgrevink PC: Prescription pattern of codeine for non-malignant pain: a pharmacoepidemiological study from the Norwegian Prescription Database. Acta Anaesthesiol Scand 2009; 53: 627-633.
39. Armand C, Thirion X, Saillard C, Lapeyre-Mestre M, Lambert H: Neocodion misuse: Evolution between 1992 and 2002. Therapie 2004; 59: 547-553. (Pubitemid 40051548)
40. Tjaderborn M, Jonsson AK, Ahlner J, Hagg S: Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol Drug Saf 2009; 18: 1192-1198.
41. Simonsen KW, Normann PT, Ceder G, Vuori E, Thordardottir S, Thelander G, Hansen AC, Teige B, Rollmann D: Fatal poisoning in drug addicts in the Nordic countries in 2007. Forensic Sci Int 2011; 207: 170-176.
42. Gibaja V, Seyer D, Lambert H, Kahn J: Prescription and misuse of fentanyl: results from a survey from the Medical Department of North East Social Security (France), over years 2007-2009. Fundam Clin Pharmacol 2011; 25: 75.
43. Beau-Salinas F, Jonville-Bera AP, Cissoko H, Bensouda-Grimaldi L, Autret-Leca E: Drug dependence associated with triptans and ergot derivatives: a case/non-case study. Eur J Clin Pharmacol 2010; 66: 413-417.
44. Perearnau P, Vuillemet F, Schick J, Weill G: Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable (in French). Rev Neurol (Paris) 2006; 162: 347-357.
45. Bramness JG, Furu K, Engeland A, Skurtveit S: Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2007; 64: 210-218. (Pubitemid 47063238)
46. Hojsted J, Sjogren P: Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007; 11: 490-518. (Pubitemid 46670780)
47. Radat F, Creac'h C, Guegan-Massardier E, Mick G, Guy N, Fabre N, Giraud P, Nachit-Ouinekh F, Lanteri-Minet M: Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache 2008; 48: 1026-1036. (Pubitemid 351952107)
48. Lundqvist C, Aaseth K, Grande RB, Benth JS, Russell MB: The severity of dependence score correlates with medication overuse in persons with secondary chronic headaches. The Akershus study of chronic headache. Pain 2010; 148: 487-491.
49. Stafford N: At least 25% of elderly residents of German nursing homes are addicted to psychotropic drugs, report claims. Br Med J 2010; 340.
50. Leikola S, Dimitrow M, Lyles A, Pitkälä K, Airaksinen M: Potentially inappropriate medication use among Finnish non-institutionalized people aged 6 65 years: a registerbased, cross-sectional, national study. Drugs Aging 2011; 28: 227-236.
51. Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, Martin-Santos R, Torrens M: Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment. Subst Use Misuse 2008; 43: 612-632. (Pubitemid 351507738)
52. Moratti E, Kashanpour H, Lombardelli T, Maisto M: Intravenous misuse of buprenorphine characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig 2010; 30: 3-11.
53. Scherbaum N, Kluwig J, Meiering C, Gastpar M: Use of illegally acquired medical opioids by opiate-dependent patients in detoxification treatment. Eur Addict Res 2005; 11: 193-196. (Pubitemid 41191614)
54. Roche A, McCabe S, Smyth BP: Illicit methadone use and abuse in young people accessing treatment for opiate dependence. Eur Addict Res 2008; 14: 219-225.
55. Pauly V, Frauger E, Pradel V, Rouby F, Berbis J, Natali F, Reggio P, Coudert H, Micallef J, Thirion X: Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse. Drug Alcohol Depend 2011; 113: 29-36.
56. Cazorla C, de Cardenal DG, Schuhmacher H, Thomas L, Wack A, May T, Rabaud C: Infectious complications and misuse of highdose buprenorphine (in French). Presse Med 2005; 34: 719-724. (Pubitemid 40868354)
57. Hakansson A, Medvedeo A, Andersson M, Berglund M: Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur Addict Res 2007; 13: 207-215. (Pubitemid 47414338)
58. Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88: 75-78. (Pubitemid 46400304)
59. Simojoki K, Lillsunde P, Lintzeris N, Alho H: Bioavailability of buprenorphine from crushed and whole buprenorphine (Subutex) tablets. Eur Addict Res 2010; 16: 85-90.
60. Feroni I, Peretti-Watel P, Paraponaris A, Masut A, Ronfle E, Mabriez JC, Obadia Y: French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse? J Addict Dis 2005; 24: 7-22. (Pubitemid 41542392)
61. Stavropoulou C: Non-adherence to medication and doctor-patient relationship: evidence from a European survey. Patient Educ Couns 2011; 83: 7-13.
62. Bacha J, Reast S, Pearlstone A: Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Rel Clin Probl 2010; 12: 9-19.
63. Man LH, Best D, Gossop M, Stillwell G, Strang J: Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. Eur Addict Res 2004; 10: 35-40. (Pubitemid 37505843)
64. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W: Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003; 98: 1371-1378. (Pubitemid 37297243)
65. Jaffe JH, Bloor R, Crome I, Carr M, Alam F, Simmons A, Meyer RE: A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004; 99: 165-173. (Pubitemid 38250751)
66. Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P: Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007; 64: 198-209. (Pubitemid 47063241)
67. Micallef-Roll J, Lapeyre-Mestre M: Second Meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). I. How to evaluate and prevent the abuse and dependence on hypnotic/ anxiolytic drugs? Therapie 2009; 64: 355-364.
68. Johansson BA, Berglund M, Hanson M, Pohlen C, Persson I: Dependence on legal psychotropic drugs among alcoholics. Alcohol Alcohol 2003; 38: 613-618. (Pubitemid 37455861)
69. Seblova J, Polanecky V, Sejda J, Studnickova B: Trends in substance abuse by teenagers in the Czech Republic. J Emerg Med 2005; 28: 95-100. (Pubitemid 40126781)
70. Csoboth CT, Birkas E, Purebl G: Physical and sexual abuse: risk factors for substance use among young Hungarian women. Behav Med 2003; 28: 165-171. (Pubitemid 37474274)
71. Hurwitz W: The challenge of prescription drug misuse: a review and commentary. Pain Med 2005; 6: 152-161. (Pubitemid 40590529)
72. DuPont RL: Prescription drug abuse: an epidemic dilemma. J Psychoactive Drugs 2010; 42: 127-132.
73. Fatseas M, Auriacombe M: Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007; 9: 358-364. (Pubitemid 47559356)
74. Pradel V, Frauger E, Thirion X, Ronfle E, Lapierre V, Masut A, Coudert C, Blin O, Micallef J: Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18: 36-43.
75. Lavie E, Fatséas M, Daulouède JP, Denis C, Dubernet J, Cattan L, Auriacombe M: Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002. Patient Prefer Adherence 2008; 2: 369-378.
76. Bergmann JF: Self-medication: from European regulatory directives to therapeutic strategy. Fundam Clin Pharmacol 2003; 17: 275-280.
77. Fermont I: Misuse of drugs: conclusions of the pharmacovigilance workshops in La Baule, France. Therapie 2002; 57: 283-288. (Pubitemid 35190861)
78. Repantis D, Schlattmann P, Laisney O, Heuser I: Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010; 62: 187-206.
79. Deutsche Angestellten Krankenkasse (DAK). Gesundheitsreport 2009: Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. Hamburg, DAK, 2009.
80. Robert Koch-Institut (RKI): KOLIBRI Studie zum Konsum Leistungsbeeinflussender Mittel in Alltag und Freizeit: Ergebnisbericht. Berlin, RKI, 2011.
81. Deutsche Hauptstelle für Suchtfragen (DHS). Hirndoping: die Position der Deutschen Hauptstelle für Suchtfragen e.V. (DHS). Hamm, DHS, 2011.